Literature DB >> 20553262

The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer.

Simon R J Bott1, Hashim U Ahmed, Richard G Hindley, Ahmad Abdul-Rahman, Alex Freeman, Mark Emberton.   

Abstract

OBJECTIVE: To determine the pathological characteristics of radical prostatectomy specimens with respect to index and secondary lesions.
METHODS: A total of 100 consecutive radical prostatectomy specimens examined at a single hospital were assessed. Patients undergoing salvage prostatectomy or those who had received neoadjuvant hormonal manipulation were excluded. Preoperative data and the number, volume and Gleason grade of each tumour focus were recorded. Criteria used to define a clinically significant lesion were tumour volume ≥0.5 mL and/or Gleason pattern 4 or 5 and/or extra-capsular disease.
RESULTS: Overall, 374 foci were examined. The median number of tumours per patient was 3.5 (range 1-15). The overall median tumour volume was 1.4 mL (range 0.1-18.2), the median volume of the largest (index) tumour was 0.95 mL (range 0.1-18.2) and the median volume of the largest secondary tumour was 0.2 mL (range 0.05-1.7). There were no patients in whom the index lesion was insignificant and secondary tumours were significant (by grade or extra-capsular disease). Seventy-seven fulfilled the clinical parameters of low-to-intermediate-risk disease. If focal therapy can be delivered with the aim of ablating all clinically significant disease, with untreated areas harbouring no cancer or clinically insignificant disease, between 58.5 and 67.5% might have been suitable for such a strategy.
CONCLUSIONS: The proportion of men with low-to-intermediate-risk prostate cancer who may potentially be suitable for a focal therapy approach is unknown. The key question is whether the volume of individual lesions points to clinically significant cancer and whether ablation of these lesions alone would lead to cancer control. This research question is currently undergoing evaluation within a prospective clinical trial.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2010        PMID: 20553262     DOI: 10.1111/j.1464-410X.2010.09436.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  37 in total

Review 1.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 2.  Image guidance in the focal treatment of prostate cancer.

Authors:  Anthony N Hoang; Dmitry Volkin; Nitin K Yerram; Srinivas Vourganti; Jeffrey Nix; W Marston Linehan; Bradford Wood; Peter A Pinto
Journal:  Curr Opin Urol       Date:  2012-07       Impact factor: 2.309

3.  Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection.

Authors:  Andrew B Rosenkrantz; Hersh Chandarana; Nicole Hindman; Fang-Ming Deng; James S Babb; Samir S Taneja; Christian Geppert
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

Review 4.  [Prostate gland - what would urologists like to know from radiologists?]

Authors:  U B Liehr; D Baumunk; S Blaschke; F Fischbach; B Friebe; F König; A Lemke; P Mittelstädt; M Pech; M Porsch; J Ricke; D Schindele; S Siedentopf; J J Wendler; M Schostak
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

Review 5.  [Treatment of localized prostate cancer with high-intensity focused ultrasound].

Authors:  D Baumunk; M Schostak
Journal:  Urologe A       Date:  2015-02       Impact factor: 0.639

6.  Identification of the prostate cancer index lesion by real-time elastography: considerations for focal therapy of prostate cancer.

Authors:  Jochen Walz; Myriam Marcy; Jeanne Thomassin Pianna; Serge Brunelle; Gwenaelle Gravis; Naji Salem; Franck Bladou
Journal:  World J Urol       Date:  2011-05-26       Impact factor: 4.226

7.  Focal therapy for prostate cancer - where are we in 2011?

Authors:  Michael S Borofsky; Timothy Ito; Andrew B Rosenkrantz; Samir S Taneja
Journal:  Ther Adv Urol       Date:  2011-08

Review 8.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

Review 9.  Benchmarks for success in focal therapy of prostate cancer: cure or control?

Authors:  Hashim U Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2010-09-10       Impact factor: 4.226

10.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.